Proffer Agreements in Healthcare Fraud Cases

Proffer Agreements in Healthcare Fraud Cases

The proffer agreement is the government’s most efficient instrument for converting a defendant into a witness, and in healthcare fraud cases, it operates with a precision that most defendants do not appreciate until the session has concluded. Federal prosecutors do not extend proffer invitations because they are curious about what happened. The invitation arrives because the government has assembled a body of evidence, because the loss amount justifies the resources of the Health Care Fraud Unit, and because the defendant occupies a position in the scheme where cooperation could implicate others. The Department of Justice charged 324 defendants in its 2025 National Health Care Fraud Takedown, across fifty federal districts, on allegations involving more than fourteen billion dollars in fraudulent claims. In an enforcement operation of that scale, the proffer is not a courtesy extended to the accused. It is a component of prosecutorial design.

One enters the room believing the session is an opportunity to explain. One leaves having provided a map.

The Proffer Letter and Its Provisions

Before any session occurs, the defendant and counsel sign a proffer letter, sometimes called a “Queen for a Day” agreement. The document is short. The letter provides that the government will not use the defendant’s direct statements in its case in chief. It reserves the right to use those statements for impeachment if the defendant later testifies inconsistently at trial. It reserves the right to pursue any investigative lead generated by the session. And it states, in language that reads as boilerplate but functions as the operative framework of the entire arrangement, that no promises of immunity or a plea agreement have been made.

The distinction between what is protected and what is not requires close reading. The defendant’s words cannot be introduced as direct evidence at trial, but the evidence those words generate, the witnesses those words identify, the documents those words locate, all of that is admissible without restriction. This is the derivative use provision. In healthcare fraud cases, where billing records, electronic health records, and years of correspondence form a dense evidentiary web, the derivative pathways multiply with a speed that catches most defendants off guard.

A physician who mentions a meeting with a laboratory representative has, in that sentence, given the government a date, a relationship, and a line of inquiry it may not have possessed before the session began. The agents in the room are taking notes. They are not recording the physician’s words for their direct evidentiary value so much as cataloguing the directions those words suggest.

The proffer letter will also specify that it is not a cooperation agreement. A cooperation agreement contemplates a specific outcome: a plea, a sentencing recommendation, a motion under USSG §5K1.1. The proffer letter contemplates nothing beyond the session itself, and whether a cooperation agreement follows depends on what the government perceives as the value and truthfulness of what was disclosed. That evaluation belongs to the government alone.

Derivative Use and the Kastigar Framework

The Supreme Court’s 1972 decision in Kastigar v. United States established that use and derivative use immunity is sufficient to replace the Fifth Amendment privilege against self-incrimination. Under a grant of statutory immunity, the government bears the heavy burden of demonstrating that all evidence it proposes to introduce was derived from a source independent of the compelled testimony. Under a standard proffer letter, the protections are considerably narrower, because the defendant has contractually agreed to waive derivative use protections.

That distinction deserves attention, because it is where the architecture of the proffer agreement departs from what most defendants expect. Statutory immunity requires the government to prove, at a hearing, that its evidence comes from an independent source. The proffer letter eliminates that hearing. The Kastigar waiver embedded in most federal proffer letters permits the government to follow every lead the defendant’s statements produce, without any subsequent obligation to demonstrate that the evidence would have been discovered through other means. What remains is use immunity in its narrowest form: the government will not play a recording of the defendant’s voice at trial. It will present the billing records, the testimony of co-conspirators, and the electronic communications that the defendant’s own words helped the government locate.

In healthcare fraud prosecutions, where the evidentiary record consists of thousands of claims, hundreds of patient files, and years of correspondence between providers, laboratories, and referral sources, the derivative use problem is not a hypothetical risk discussed in law review articles. A defendant who, in the course of explaining a billing arrangement, mentions that a particular wholesaler offered volume discounts tied to referral numbers has given the government an Anti-Kickback Statute theory it may not have been developing. A defendant who describes the workflow of a telemedicine platform (one in which, it should be noted, the prescribing physician never examined the patient whose chart bore the physician’s signature) has confirmed the elements of a scheme the government suspected but could not prove from claims data alone.

The standard proffer letter in the Southern District of Florida or the Eastern District of Texas, which have served as focal points for healthcare fraud enforcement, will contain language permitting derivative use “without restriction.” Courts have upheld this language as a matter of contract law. The defendant agreed to the terms. The terms are enforceable. Whether the resulting evidence would have been discovered independently is a question the government is not required to answer.

I am less certain about how uniformly courts across circuits would treat a challenge to aggressive derivative use where the proffer was the sole source of a critical lead, though in practice such challenges seldom succeed because the proffer letter’s language is broad enough to foreclose the argument before it begins.

The proffer does not give the government your words. It gives the government your knowledge. The difference between those two things is the difference between what is protected and what is not.

Whether the defendant’s cooperation leads to a formal agreement or dissolves into silence, the derivative information remains in the government’s possession. That asymmetry is, if we are being precise, the defining risk of the proffer session in any fraud case, and in healthcare fraud it is amplified by the volume of records available for the government to cross-reference against whatever the defendant discloses.

Whether the court intended this framework to function as an inducement to cooperation or merely failed to place meaningful limits on the government’s contractual leverage is a question worth posing, though no circuit has offered a satisfying answer.

What the Loss Amount Becomes

In federal healthcare fraud sentencing, the loss amount under USSG §2B1.1 is the dominant variable. Each threshold the loss crosses adds levels to the offense calculation, and for offenses involving a government health care program, additional enhancements apply when the loss exceeds one million, seven million, or twenty million dollars. The aggregate amount of fraudulent claims submitted constitutes prima facie evidence of intended loss under the guidelines.

The proffer session is where the loss amount grows. A defendant who arrived at the U.S. Attorney’s office facing allegations involving a defined set of claims may, in the course of providing full disclosure, reveal that similar billing practices extended across additional providers, additional time periods, additional programs. The government’s obligation under the proffer letter is to refrain from using the defendant’s direct statements. It has no obligation to ignore the scope of conduct those statements revealed. Under the relevant conduct provisions of §1B1.3, the court considers all acts that were part of the same course of conduct or common scheme, whether or not those acts were charged in the indictment.

A defendant whose initial exposure involved claims totaling several hundred thousand dollars may, by the close of a thorough proffer session, have expanded the relevant conduct to a figure that crosses the next enhancement threshold. The guidelines do not ask how the government learned about the additional conduct. The loss is the loss.

Physician Defendants and Regulatory Exposure

Healthcare fraud defendants who hold medical licenses face considerations that defendants in purely financial fraud do not encounter. Cooperation through a proffer session demands full disclosure of one’s own conduct, and for a physician, that disclosure implicates the medical license, the DEA registration, and eligibility to participate in federal healthcare programs. OIG exclusion following a healthcare fraud conviction is mandatory. The exclusion proceedings operate on a preponderance standard, on a separate timeline, under different rules. A physician can prevail at trial and still face exclusion based on the underlying allegations, because acquittal in a criminal case does not bind the administrative proceeding.

Preparation for a proffer session in a healthcare fraud case therefore involves a calculus that extends beyond the criminal exposure. Counsel must evaluate the strength of the government’s evidence, the realistic sentencing range with and without cooperation, and the civil False Claims Act liability that runs parallel to the criminal case and carries treble damages. The FCA recoveries for fiscal year 2025 exceeded six billion dollars, with healthcare matters accounting for the vast majority. The civil side of the case does not disappear because the defendant cooperated on the criminal side, and the regulatory consequences exist in a space that no plea agreement can reach.

And there is a particular difficulty that physician defendants encounter when they believe, sometimes with reason, that their billing practices were aggressive but not fraudulent. The proffer session does not accommodate that distinction well. A physician who enters the room intending to explain that the procedures were medically necessary, that the upcoding reflected clinical judgment rather than intent to defraud, will find prosecutors who are trained to convert explanations into admissions. The statement “I knew we were pushing boundaries on the billing codes” establishes knowledge and willfulness, which are the statutory elements the government needs. The statement “everyone in the practice did it this way” establishes a pattern of conduct. The minimization the physician believes is protective becomes, in the hands of a prosecutor conducting a follow-up question, confirmation.

The proffer session functions, for a physician, somewhat the way a building inspection functions for a structure that has already been condemned: the inspection does not cause the problems it identifies, but it documents them in a form that makes demolition easier to authorize. The physician’s words do not create the fraud. They organize the government’s evidence of it.

In something like forty of the healthcare fraud matters our firm has reviewed, the defendant’s initial instinct was to treat the proffer as an opportunity for persuasion rather than an exchange of information. That instinct misperceives the purpose of the session. Persuasion is not what the room was constructed for.

Sentencing and the 5K1.1 Departure

Six months after a successful proffer leads to a cooperation agreement, after the defendant has provided testimony at a co-defendant’s trial or furnished information that resulted in additional charges, the government may file a motion under USSG §5K1.1 attesting that the defendant rendered substantial assistance in the investigation or prosecution of another person. Only the government can file this motion. The court cannot grant a departure without it.

The court considers the significance and usefulness of the assistance, the truthfulness and completeness of the information, the nature and extent of the cooperation, any risk or injury to the defendant or the defendant’s family, and the timeliness of the assistance. In healthcare fraud cases, where loss amounts are large and guideline ranges severe, a §5K1.1 departure can reduce a sentence by half or more. The government may also move under 18 U.S.C. §3553(e) for a sentence below a mandatory minimum.

The government’s discretion over whether to file the motion is, as a practical matter, unreviewable. Courts have held that refusal to file a §5K1.1 motion can be challenged only on grounds of unconstitutional motive or bad faith. That standard is almost impossible to satisfy. A defendant who cooperated in good faith, who disclosed everything asked, who testified when called, may still find that the government declines to file the motion because it concluded the assistance was not substantial enough, or because the co-defendant’s case resolved before the cooperator’s testimony became necessary. The government’s assessment of value is the government’s assessment of value.

The statute does not specify a relationship between the extent of assistance and the magnitude of the departure. That ambiguity is where experienced counsel can affect the outcome, though I would not overstate the degree of control any attorney exercises over a process in which the government holds the initial and final word on the motion itself.

The Scope of the Decision

What does the decision to proffer in a healthcare fraud case actually commit one to? It commits the defendant to a version of the case in which speech replaces silence, in which the government’s evidentiary position improves whether or not the cooperation leads to a formal agreement, and in which the loss amount may expand to encompass conduct the defendant identified rather than concealed. It commits the defendant to a calculation in which the potential reward, a §5K1.1 departure, a reduced sentence, a less severe plea, exists entirely within the government’s discretion.

The question is not whether to proffer. The question is whether the evidence the government already possesses makes silence a viable alternative, and whether the sentencing exposure without cooperation is something the defendant is prepared to accept. In cases where the evidence is strong and the loss amount is large, the proffer may represent the only realistic path to a sentence that permits a physician to return to practice, a business owner to preserve something, a defendant to measure the consequence in years rather than decades.

What the proffer agreement cannot contain, what no contractual provision can hold, is certainty about what comes next. The government evaluates. The government decides. The defendant, having spoken, waits.

For physicians, practice owners, and healthcare executives under federal investigation, a consultation with this firm assumes nothing and costs nothing. It is where the variables that shape this decision are assembled into something one can read with clarity.